| Lauren Suggs, MD | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 847-0000 | |
| Not Available |
| Full Name | Lauren Suggs |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 9 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043605579 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.
EU-funded researchers and industrial partners are developing a system that allows a person to control the movement of a prosthetic hand simply by thinking of commands. A patient recently underwent surgery to implant some of the project's ground-breaking technologies.
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.
Researchers found that more than 97 percent of the surgeries for appendicitis were laparoscopic, or minimally invasive, and most patients were discharged the same day or the next day. Only 3 percent of the procedures resulted in complications.
For people contemplating a hip or knee replacement, the prospect of a long post-surgical recovery can be a daunting one. The grueling rehabilitation sessions, the frustration of re-learning everyday movements, the weeks of waiting to return to "normal"— it's almost enough to make patients reconsider surgery.
› Verified 1 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.
EU-funded researchers and industrial partners are developing a system that allows a person to control the movement of a prosthetic hand simply by thinking of commands. A patient recently underwent surgery to implant some of the project's ground-breaking technologies.
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.
Researchers found that more than 97 percent of the surgeries for appendicitis were laparoscopic, or minimally invasive, and most patients were discharged the same day or the next day. Only 3 percent of the procedures resulted in complications.
For people contemplating a hip or knee replacement, the prospect of a long post-surgical recovery can be a daunting one. The grueling rehabilitation sessions, the frustration of re-learning everyday movements, the weeks of waiting to return to "normal"— it's almost enough to make patients reconsider surgery.
› Verified 1 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.
EU-funded researchers and industrial partners are developing a system that allows a person to control the movement of a prosthetic hand simply by thinking of commands. A patient recently underwent surgery to implant some of the project's ground-breaking technologies.
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.
Researchers found that more than 97 percent of the surgeries for appendicitis were laparoscopic, or minimally invasive, and most patients were discharged the same day or the next day. Only 3 percent of the procedures resulted in complications.
For people contemplating a hip or knee replacement, the prospect of a long post-surgical recovery can be a daunting one. The grueling rehabilitation sessions, the frustration of re-learning everyday movements, the weeks of waiting to return to "normal"— it's almost enough to make patients reconsider surgery.
› Verified 1 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.
EU-funded researchers and industrial partners are developing a system that allows a person to control the movement of a prosthetic hand simply by thinking of commands. A patient recently underwent surgery to implant some of the project's ground-breaking technologies.
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.
Researchers found that more than 97 percent of the surgeries for appendicitis were laparoscopic, or minimally invasive, and most patients were discharged the same day or the next day. Only 3 percent of the procedures resulted in complications.
For people contemplating a hip or knee replacement, the prospect of a long post-surgical recovery can be a daunting one. The grueling rehabilitation sessions, the frustration of re-learning everyday movements, the weeks of waiting to return to "normal"— it's almost enough to make patients reconsider surgery.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Suggs, MD 22 S Greene St, Room N3e09, Baltimore, MD 21201-1544 Ph: () - | Lauren Suggs, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 |
News Archive
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.
EU-funded researchers and industrial partners are developing a system that allows a person to control the movement of a prosthetic hand simply by thinking of commands. A patient recently underwent surgery to implant some of the project's ground-breaking technologies.
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.
Researchers found that more than 97 percent of the surgeries for appendicitis were laparoscopic, or minimally invasive, and most patients were discharged the same day or the next day. Only 3 percent of the procedures resulted in complications.
For people contemplating a hip or knee replacement, the prospect of a long post-surgical recovery can be a daunting one. The grueling rehabilitation sessions, the frustration of re-learning everyday movements, the weeks of waiting to return to "normal"— it's almost enough to make patients reconsider surgery.
› Verified 1 days ago
Nadia Ghallab, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Dr. Christopher Dwight Huston, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2264 | |
Beth Diane Kirkpatrick, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Magdalena Anna Zeglin, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |